Allergy-related inflammatory targets

Allergy-related inflammatory targets encompass a diverse group of proteins and signaling molecules that drive the hypersensitivity reactions characteristic of atopic diseases (StatPearls, 2023). This category includes the antibody Immunoglobulin E (IgE), which mediates the activation of mast cells and basophils, as well as Th2-type cytokines like IL-4, IL-5, and IL-13 that coordinate eosinophilic inflammation and mucus production (Nature Reviews Immunology, 2018). Other significant targets include the Histamine H1 receptor and cysteinyl leukotriene receptors, which are responsible for acute symptoms like vasodilation and bronchoconstriction (Journal of Allergy and Clinical Immunology, 2020). Modern therapeutic strategies often utilize monoclonal antibodies, such as Omalizumab or Dupilumab, to specifically inhibit these pathways, significantly improving outcomes for patients with severe asthma and atopic dermatitis (NEJM, 2021). Because this term describes a broad class of molecules rather than a single therapeutic target, it is considered a collective grouping of various distinct biological entities rather than a specific canonical target.

Other names

Type 2 inflammatory targetsAtopic disease mediatorsTh2 cytokine pathway targetsAllergic inflammation mediators

Inhibition of IgE binding to FceRI (Omalizumab), blockade of IL-4 and IL-13 signaling via the IL-4Ra subunit (Dupilumab), neutralization of IL-5 (Mepolizumab) or the IL-5 receptor (Benralizumab) to reduce eosinophil survival, and antagonism of histamine H1 or leukotriene receptors (StatPearls, 2023).